Venetoclax combined with other medications for treating multiple myeloma

Phase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) in t(11;14) Multiple Myeloma

This study is testing a new combination of medications, including venetoclax, to see how well it works and what the best dose is for people with multiple myeloma who have a specific genetic marker.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 100 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Mayo Clinic (Academic / other)
• Drugs / interventions: chemotherapy, daratumumab
• Locations: 1 site (Rochester, Minnesota)
• Trial ID: NCT06042725 on ClinicalTrials.gov

What this trial studies

This phase I trial evaluates the safety and optimal dosage of venetoclax when used alongside lenalidomide and dexamethasone, daratumumab and dexamethasone, or a combination of daratumumab, lenalidomide, and dexamethasone in patients with multiple myeloma. The study aims to determine the recommended phase II dose of venetoclax for patients with a specific genetic marker (t(11;14)). Participants will be monitored for treatment-related side effects and overall response to the treatment. Additionally, the study will explore the impact of treatment on patients' quality of life.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with active multiple myeloma and the t(11;14) genetic marker, either newly diagnosed or relapsed after prior therapy.

Not a fit: Patients who have undergone stem cell transplant or have not been previously treated with venetoclax may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment approach could improve outcomes for patients with multiple myeloma, particularly those with the t(11;14) genetic marker.

How similar studies have performed: While this approach is novel in its specific combination, similar studies have shown promise in treating multiple myeloma with targeted therapies.

Eligibility criteria

Inclusion Criteria:

* PRE-REGISTRATION: Diagnosis of active MM with bone marrow plasma cell fluorescence in situ hybridization (FISH) test run under an Investigational Device Exemption (IDE) demonstrating of t(11;14), either from time of diagnosis or confirmed with IDE at Mayo Clinic after time of diagnosis, during screening period for study. Note: Samples tested beyond 72 hours from the collection will not be considered adequate for trial enrollment
* PRE-REGISTRATION: Group 1 - At least one prior line of therapy which did not include venetoclax
* PRE-REGISTRATION: Group 2 - No more than 1 cycle of any commonly used myeloma regimen for treatment of newly diagnosed MM
* PRE-REGISTRATION: Patient is not being considered for stem cell transplant (group 2, newly diagnosed only)
* REGISTRATION: Age ≥ 18 years
* REGISTRATION: Calculated creatinine clearance (using Cockcroft-Gault equation) ≥ 30 mL/min (obtained ≤ 14 days prior to registration)
* REGISTRATION: Absolute neutrophil count (ANC) ≥ 1000/uL (without growth factor support) (obtained ≤ 14 days prior to registration)
* REGISTRATION: Un-transfused Platelet count ≥ 75000/uL (≥ 50,000/uL if marrow plasma cells \[PC\]% \> 50%) (obtained ≤ 14 days prior to registration)
* REGISTRATION: Hemoglobin ≥ 8.0 g/dL (transfusion permitted) (obtained ≤ 14 days prior to registration)
* REGISTRATION: Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (known Gilbert's syndrome are allowed provided bilirubin ≤ 2.5 mg/dL) (obtained ≤ 14 days prior to registration)
* REGISTRATION: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN (obtained ≤ 14 days prior to registration)
* REGISTRATION: Alkaline phosphatase ≤ 750 U/L (obtained ≤ 14 days prior to registration)
* REGISTRATION: Measurable disease of multiple myeloma as defined by at least ONE of the following:

  * Serum monoclonal protein ≥ 1.0 g/dL
  * ≥ 200 mg of monoclonal protein in the urine on 24 hour electrophoresis
  * Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
* REGISTRATION: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
* REGISTRATION: Provide written informed consent
* REGISTRATION: Ability to complete questionnaire(s) by themselves or with assistance
* REGISTRATION: Negative serum pregnancy test done ≤ 7 days prior to registration, for women of childbearing potential only
* REGISTRATION: Willing to follow strict birth control measures as suggested by the study
* REGISTRATION: Female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

  * Is not a woman of childbearing potential (WOCBP) OR
  * Due to lenalidomide being a thalidomide analogue with risk for embryo-fetal toxicity and prescribed under a pregnancy prevention/controlled distribution program, WOCBP participants will be eligible if they commit to either:

    * Abstain continuously from heterosexual sexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR
    * To use birth control as follows:

      * Two methods of reliable birth control (one method that is highly effective and one additional effective (barrier) method), beginning 4 weeks prior to initiating treatment with lenalidomide, during therapy, during dose interruptions and continuing for 4 weeks following discontinuation of lenalidomide treatment
* REGISTRATION: Male participants are eligible to participate if they agree to the following from the time of first dose of study treatment until 28-days after the last dose of lenalidomide, to allow for clearance of any altered sperm:

  * Refrain from donating sperm PLUS either:

    * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR
    * Must agree to use contraception/barrier as detailed below:

      * Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of \< 1% per year as when having sexual intercourse with a woman of childbearing potential (including pregnant females)
* REGISTRATION: Life expectancy ≥ 12 weeks
* REGISTRATION: Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
* REGISTRATION: Willing to provide research bone marrow aspirate specimen
* REGISTRATION: Willing to follow the requirements of the Revlimid (Registered Trademark) Risk Evaluation and Mitigation Strategy (REMS) program. Note: Exception for Group 2 patients enrolled on Arm A

Exclusion Criteria:

* PRE-REGISTRATION: History of any active malignancy within the past 2 years prior to screening, with the exception of:

  * Adequately treated carcinoma in situ of the uterine cervix
  * Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin
  * Asymptomatic prostate cancer with no requirement for therapy
  * Previous malignancy surgically resected (or treated with other modalities) with curative intent
* REGISTRATION: Other concurrent chemotherapy or any ancillary therapy considered investigational

  * Note: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment
* REGISTRATION: Major surgery ≤ 14 days prior to study registration
* REGISTRATION: History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
* REGISTRATION: Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
* REGISTRATION: Administration of strong/moderate CYP3A inhibitors or inducers ≤ 28 days prior to registration
* REGISTRATION: Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
* REGISTRATION: Participation in other clinical trials, including those with other investigational agents not included in this trial, ≤ 30 days prior to registration
* REGISTRATION: Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of venetoclax including difficulty swallowing REGISTRATION: Heart failure \> New York Heart Association (NYHA) class II
* REGISTRATION: Presence of positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment

  * Note: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative hepatitis C RNA test is obtained
  * Note: Hepatitis RNA testing is optional and participants with negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing

Where this trial is running

Rochester, Minnesota

• Mayo Clinic in Rochester — Rochester, Minnesota, United States (Recruiting)

Study contacts

• Principal investigator: Shaji K. Kumar, MD — Mayo Clinic in Rochester
• Study coordinator: Clinical Trials Referral Office

Conditions Multiple Myeloma